RBC Capital analyst Conor McNamara maintains $Maravai LifeSciences (MRVI.US)$ with a buy rating, and adjusts the target price from $17 to $13.
According to TipRanks data, the analyst has a success rate of 38.4% and a total average return of -7.3% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Maravai LifeSciences (MRVI.US)$'s main analysts recently are as follows:
Maravai Lifesciences reported a Q3 loss wider than anticipated. This comes after consistent solid performance in comparison to guidance across three consecutive quarters. The company has been impacted by the challenging biotech spending landscape and the irregular order patterns from customers that are characteristic of their sector.
Maravai Lifesciences' third-quarter results fell short of expectations, with performance lagging in both segments compared to projections. The company indicated a decline in research/discovery demand, an absence of significant drop-in orders, and a postponement of several GMP program timings into 2025.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
加皇資本市場分析師Conor McNamara維持$Maravai LifeSciences (MRVI.US)$買入評級，並將目標價從17美元下調至13美元。
根據TipRanks數據顯示，該分析師近一年總勝率為38.4%，總平均回報率為-7.3%。
此外，綜合報道，$Maravai LifeSciences (MRVI.US)$近期主要分析師觀點如下：
Maravai Lifesciences報告稱，第三季度的虧損超出預期。這是在連續三個季度的預期表現持續穩健之後發生的。該公司受到了充滿挑戰的生物技術支出格局以及該行業特有的客戶不規則訂單模式的影響。
Maravai Lifesciences第三季度的業績低於預期，與預期相比，這兩個板塊的表現均落後。該公司表示，研究/發現需求下降，沒有大量的臨時訂單，並且幾項GMP計劃的時間安排已推遲到2025年。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
